Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Relistor

Deal Watch November 2015

Strategic business expansion or financial engineering?In November Pfizer at long last found a willing acquisition target that may provide the tax inversion it has been desperate to achieve since its...

Deal Watch October 2015

A bumper crop of deals with seven transactions of $1bn or more

- PMLiVE

FDA clears Takeda’s oral multiple myeloma drug

Ninlaro is the first oral proteasome inhibitor to get a green light from the FDA

- PMLiVE

PBMs drop Philidor, and Valeant follows suit

Comes after allegations of impropriety

- PMLiVE

Valeant adds member to board of directors

President of ValueAct Capital G. Mason Morfitadded to team

- PMLiVE

Valeant shares plummet on claims of inflated revenues

California lawsuit raises questions about relationship with Philidor Rx

Pharma deals in September 2015

September saw an interesting mix of deal types and structures, disease areas and companies hitting our Deal Watch radar. Oncology deals continue to be prominent, but the month also saw...

- PMLiVE

Bio investors react as Clinton tweet pledges pricing crackdown

Pharma companies come under scrutiny for pricing policies

Pharma deals in August 2015

During a busy month AstraZeneca, Sanofi and Shire were among those hitting the headlines

- PMLiVE

Takeda’s ixazomib moves closer to US approval

Wins priority review from the FDA

- PMLiVE

Valeant adds Robert Hale to board of directors

And Jeffrey Ubben resigns from the board

Celgene building

Myeloma market set to be $9bn by 2021

New research shows it will pushed by a growing prevalence of the disease

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links